EGFR and exanthem: Different types of first-line EGFR-TKIs were administered to the two groups because the frequency of skin rash differed depending on the type of EGFR-TKI; more patients received erlotinib and afatinib in the MINO group (37.5 and 37.5%, respectively), whereas more received gefitinib and osimertinib in the control group (40.6 and 34.0%, respectively) (Table 1).